Followers | 9 |
Posts | 1278 |
Boards Moderated | 1 |
Alias Born | 09/09/2000 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 22, 2002 4:58:20 PM
Take a look at the site: http://www.okid.com
Keep an eye out on the web for upcoming information about JANX and the cyber bear.
Wise
Wise
Recent JANX News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:06:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:28:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:20:47 PM
- Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights • Business Wire • 08/07/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:00:50 PM
- Janux Therapeutics Announces Updates to Board of Directors • Business Wire • 07/22/2024 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 09:02:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 11:02:49 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/08/2024 01:13:58 PM
- Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights • Business Wire • 05/07/2024 08:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 09:47:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:11:29 PM
- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • Business Wire • 03/08/2024 09:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 10:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 10:11:11 PM
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants • Business Wire • 02/29/2024 06:22:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/29/2024 02:55:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:15:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:50:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:23:20 PM
- Janux Therapeutics Announces Proposed Public Offering of Common Stock • Business Wire • 02/27/2024 10:00:00 PM
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors • Business Wire • 02/26/2024 09:05:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM